A comprehensive overview of clinical research on dexmedetomidine in the past 2 decades: A bibliometric analysis

Kong, Hao; Li, Mo; Deng, Chonghai; Wu, Yujia; He, Shu-Ting; Mu, Dong-Liang

doi:10.3389/fphar.2023.1043956

Cited by 10 publications

(8 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, we found that the protective effect of Dex on X-ray radiation-induced myocardial injury was through inhibiting autophagy. As Dex has been extensively used in clinical practice [ 52 ], our data may extend the possibility of using Dex for radiation-induced myocardial injury.…”

Section: Discussionmentioning

confidence: 70%

Dexmedetomidine ameliorates x-ray-induced myocardial injury via alleviating cardiomyocyte apoptosis and autophagy

Zhang,

Xie,

Lian

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Radiotherapy is a primary local treatment for tumors, yet it may lead to complications such as radiation-induced heart disease (RIHD). Currently, there is no standardized approach for preventing RIHD. Dexmedetomidine (Dex) is reported to have cardio-protection effects, while its role in radiation-induced myocardial injury is unknown. In the current study, we aimed to evaluate the radioprotective effect of dexmedetomidine in X-ray radiation-treated mice. Methods 18 male mice were randomized into 3 groups: control, 16 Gy, and 16 Gy + Dex. The 16 Gy group received a single dose of 16 Gy X-ray radiation. The 16 Gy + Dex group was pretreated with dexmedetomidine (30 µg/kg, intraperitoneal injection) 30 min before X-ray radiation. The control group was treated with saline and did not receive X-ray radiation. Myocardial tissues were collected 16 weeks after X-ray radiation. Hematoxylin-eosin staining was performed for histopathological examination. Terminal deoxynucleotidyl transferase dUTP nick-end labeling staining was performed to assess the state of apoptotic cells. Immunohistochemistry staining was performed to examine the expression of CD34 molecule and von Willebrand factor. Besides, western blot assay was employed for the detection of apoptosis-related proteins (BCL2 apoptosis regulator and BCL2-associated X) as well as autophagy-related proteins (microtubule-associated protein 1 light chain 3, beclin 1, and sequestosome 1). Results The findings demonstrated that 16 Gy X-ray radiation resulted in significant changes in myocardial tissues, increased myocardial apoptosis, and activated autophagy. Pretreatment with dexmedetomidine significantly protects mice against 16 Gy X-ray radiation-induced myocardial injury by inhibiting apoptosis and autophagy. Conclusion In summary, our study confirmed the radioprotective effect of dexmedetomidine in mitigating cardiomyocyte apoptosis and autophagy induced by 16 Gy X-ray radiation.

show abstract

Section: Discussionmentioning

confidence: 70%

Dexmedetomidine ameliorates x-ray-induced myocardial injury via alleviating cardiomyocyte apoptosis and autophagy

Zhang,

Xie,

Lian

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…This drug has been introduced since 1999, and its effect on the pediatric population has been thoroughly studied. DEX can be used as a sedative agent in the intensive care setting, for procedural sedation, as an adjuvant, and even as a main anesthetic agent to babies and children undergoing surgical procedures [ 23 ]. The literature recommends an intravenous loading dose of 1 μg/kg within 10 minutes, followed by a maintenance dose of 0.7 μg/kg/hour.…”

Section: Discussionmentioning

confidence: 99%

“…Dexmedetomidine has been studied since 1999, and its use as a sedative agent for diagnostic procedures in intensive care units, as an adjuvant anesthetic, and even in painful procedures such as laryngoscopy has been well documented [ 16 , 18 – 22 ]. In fact, the majority of its studies were focused on the pediatric population [ 23 ]. Dexmedetomidine’s unique features are not comparable to other anesthetic drugs available.…”

Section: Introductionmentioning

confidence: 99%

Dexmedetomidine as a total intravenous anesthetic in pediatric patients undergoing cleft lip and palate surgery: a case series

Yahya,

Andriyanto,

Priyadi

2024

J Med Case Reports

View full text Add to dashboard Cite

Background Surgery for pediatric cleft lip and palate repair often utilizes high-dose opioids and inhaled anesthesia, thereby causing postoperative complications such as desaturation and/or severe agitation after anesthesia. These complications are detrimental to the child and medical personnel and cause tremendous psychologic stress to parents. Our aim is to decrease these complications through dexmedetomidine, an alpha-2 receptor agonist with anxiolytic, sympatholytic, and analgetic properties. Devoid of respiratory depressant effect, it allows patients to maintain effective ventilation and reduce agitation, postoperatively. Its unique anesthetic property may shed light on providing safe anesthesia and gentle emergence to this young, vulnerable population. Case presentation A total of 21 patients of Sundanese ethnicity, aged 3 months to 8 years (9 males and 12 females), underwent cleft lip or cleft palate surgery using total intravenous dexmedetomidine. Anesthesia was induced using sevoflurane, fentanyl, and propofol, and airway was secured. Intravenous dexmedetomidine 1.5 μg/kg was administered within 10 minutes, and a maintenance dose of 1.5 μg/kg/hour was continued as the sole anesthetic maintenance agent thereafter. Hemodynamics and anesthetic depth using Patient State Index (SEDLine™ monitor, Masimo Corporation, Irvine, CA, USA) were monitored carefully throughout the surgical procedure. Dexmedetomidine did not cause any hemodynamic derangements or postoperative complications in any of our patients. We found agitation in 9.5% (2/21) of patients. Conclusion Dexmedetomidine can be used as a total intravenous anesthetic agent to maintain anesthesia and provide gentle emergence to infants and young children undergoing cleft lip and palate repair.

show abstract

“…The keywords were extracted from the keyword section of articles. To avoid potential deviations, similar or same keywords with different expressions were manually standardized to correct and/or group similarities as previously suggested[ 23 - 25 ], before VOSviewer or CiteSpace analysis. Burst keywords were assessed using CiteSpace (V6.2R4 SE) with the following parameters: time slicing (from January 1994 to December 2022), years per slice (1), node type (keyword), the minimum burst duration (1 year), γ (0.39) and others (default).…”

Section: Methodsmentioning

confidence: 99%

Bibliometric analysis of the global research status and trends of mechanotransduction in cancer

Zhang,

Li,

Wang

et al. 2023

World J Clin Oncol

View full text Add to dashboard Cite

BACKGROUND The development of cancer is thought to involve the dynamic crosstalk between the tumor cells and the microenvironment they inhabit. Such crosstalk is thought to involve mechanotransduction, a process whereby the cells sense mechanical cues such as stiffness, and translate these into biochemical signals, which have an impact on the subsequent cellular activities. Bibliometric analysis is a statistical method that involves investigating different aspects (including authors’ names and affiliations, article keywords, journals and citations) of large volumes of literature. Despite an increase in mechanotransduction-related research in recent years, there are currently no bibliometric studies that describe the global status and trends of mechanotransduction-related research in the cancer field. AIM To investigate the global research status and trends of mechanotransduction in cancer from a bibliometric viewpoint. METHODS Literature on mechanotransduction in cancer published from January 1, 1900 to December 31, 2022 was retrieved from the Web of Science Core Collection. Excel and GraphPad software carried out the statistical analysis of the relevant author, journal, organization, and country information. The co-authorship, keyword co-occurrence, and keyword burst analysis were visualized with VOSviewer and CiteSpace. RESULTS Of 597 publications from 745 institutions in 45 countries were published in 268 journals with 35510 citation times. With 270 articles, the United States is a well-established global leader in this field, and the University of California system, the most productive (n = 36) and influential institution (n = 4705 citations), is the most highly active in collaborating with other organizations. Cancers was the most frequent publisher with the highest H-index. The most productive researcher was Valerie M. Weaver, with 10 publications. The combined analysis of concurrent and burst keywords revealed that the future research hotspots of mechanotransduction in cancer were related to the plasma membrane, autophagy, piezo1/2, heterogeneity, cancer diagnosis, and post-transcriptional modifications. CONCLUSION Mechanotransduction-related cancer research remains a hot topic. The United States is in the leading position of global research on mechano-oncology after almost 30 years of investigations. Research group cooperations exist but remain largely domestic, lacking cross-national communications. The next big topic in this field is to explore how the plasma membrane and its localized mechanosensor can transduce mechanical force through post-transcriptional modifications and thereby participate in cellular activity regulations and cancer development.

show abstract

A comprehensive overview of clinical research on dexmedetomidine in the past 2 decades: A bibliometric analysis

Cited by 10 publications

References 54 publications

Dexmedetomidine ameliorates x-ray-induced myocardial injury via alleviating cardiomyocyte apoptosis and autophagy

Dexmedetomidine ameliorates x-ray-induced myocardial injury via alleviating cardiomyocyte apoptosis and autophagy

Dexmedetomidine as a total intravenous anesthetic in pediatric patients undergoing cleft lip and palate surgery: a case series

Bibliometric analysis of the global research status and trends of mechanotransduction in cancer

Contact Info

Product

Resources

About